TKT Replagal "complete review"
This article was originally published in Pharmaceutical Approvals Monthly
Transkaryotic Therapies receives "complete review" letter Nov. 22 for its Fabry disease therapy Replagal (agalsidase alfa). FDA has continuing concerns regarding efficacy with the enzyme replacement therapy and will seek input from the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 14. Preliminary results from an 80-patient Phase III trial did not show a statistically significant difference from placebo for the primary renal function endpoint. TKT suggests six months was not long enough to show renal benefi
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.